Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma

Stephen T. Holgate(Southampton General Hospital), Huib A.M. Kerstjens, Giovanni Della Cioppa(Horsham Hospital), J. Thirlwell(Novartis (United Kingdom)), А. Г. Чучалин, Kian Fan Chung(NIHR Royal Brompton Cardiovascular Biomedical Research Unit), Jean‐Louis Hébert(Sorbonne Université), Jean Bousquet(Humboldt-Universität zu Berlin), Helen Fox(Novartis (United Kingdom)), Jan Lötvall(University of Gothenburg), Gert Persson
Clinical & Experimental Allergy
April 1, 2004
10.1111/j.1365-2222.2004.1916.x
Cited by 520

Related Papers

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
|European Respiratory Journal|2013|3.9k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k
Chronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN study
|Allergy|2011|1.1k